Epilepsy Is More Than an Electrical Storm: The cGAS Immune Pathway Reveals a Therapeutic Opportunity

Anti-seizure medications primarily aim to suppress abnormal neuronal firing, yet seizures remain uncontrolled in about one-third of patients even after they try multiple drugs. A study published in *Nature Neuroscience* proposes another point of intervention: repeated hyperexcitation may cause neurons to release DNA, triggering an immune response in the brain and making epilepsy not only an electrophysiological imbalance, but also a disease process continually driven by inflammation.

At the heart of this pathway is cGAS. It normally detects double-stranded DNA that should not be present in the cytoplasm and subsequently activates a type I interferon response through STING. The research team found that culture medium from hyperexcited neurons could prompt microglia to activate this signaling pathway. When microglia lacked cGAS, downstream TBK1 activation also disappeared, supporting the possibility that DNA released after neuronal damage acts as a catalyst for the immune response.

Human data provided clues to the pathway’s relevance to disease. The researchers analyzed existing single-cell data from a total of 11 hippocampal and cortical tissue samples from 6 patients with drug-resistant epilepsy. They observed strong expression of interferon-stimulated genes in some microglial populations, while pathway analysis pointed to cGAS and STING. Another dataset from drug-resistant temporal lobe epilepsy showed similar signals. Tissue staining further showed increases in both markers of neuronal DNA damage and microglial STING expression in epileptic lesions.

The team then tested causality in mice with Dravet syndrome carrying an Scn1a defect. After the Cgas gene dosage was partially reduced, spontaneous seizure-like activity decreased, and mortality after stimulation fell from 71.4% to 28.6%. Inflammatory transcriptional signatures in microglia and other glial cells were also weakened, while the expression of several abnormal genes in neurons shifted toward normal. However, reducing the gene dosage did not consistently raise the threshold for heat-induced seizures across all mouse cohorts and tests, indicating that the effect is still influenced by age, genetic background, and disease stage.

The drug experiments used TDI-6570, a cGAS inhibitor capable of entering the brain, administered to juvenile Dravet mice at 5 milligrams per kilogram per day. Treatment reduced early mortality and raised the mean threshold for heat-induced seizures from 40.9°C to 41.7°C, while suppressing interferon-related chemokines and correcting some transcriptional abnormalities in neurons and glial cells. These findings make cGAS a candidate target that could potentially complement conventional anti-seizure mechanisms, rather than merely an inflammatory marker accompanying the disease.

At this stage, the evidence remains primarily based on mice, and TDI-6570 has not yet demonstrated safety or efficacy in patients with epilepsy. The number of human samples was limited, patients and controls were not age-matched, and the sampled brain regions were not entirely consistent. In addition, whether cGAS in microglia, neurons, or multiple cell types drives the disease process remains to be clarified through cell-specific experiments. Because cGAS–STING is also an important antiviral defense, whether long-term inhibition affects protection against infection is another question that must be answered before clinical development.